Novel Prognostic Gene Mutations Identified in Chronic Lymphocytic Leukemia and Their Impact on Clinical Practice

被引：12
作者：
Campregher, Paulo Vidal [1 ]
Hamerschlak, Nelson [1 ,2 ]
机构：
[1] Hosp Israelita Albert Einstein, Dept Clin Pathol & Hematol, Sao Paulo, Brazil
[2] Hosp Israelita Albert Einstein, Dept Hematol & Bone Marrow Transplantat, Sao Paulo, Brazil
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2014年 / 14卷 / 04期
关键词：
B cell; Biological markers; Cancer; Drug resistance; Mutation; STEM-CELL TRANSPLANTATION; NOTCH1; MUTATIONS; RECURRENT MUTATIONS; SOMATIC MUTATIONS; SPLICING FACTOR; SURVIVAL; SF3B1; CLL; FLUDARABINE; TP53;
D O I：
10.1016/j.clml.2013.12.016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chronic lymphocytic leukemia (CLL) is a lymphoid malignancy characterized by progressive accumulation of mature lymphocytes in the peripheral blood, bone marrow, liver, and lymphoid organs. Although most patients with CLL have an insidious clinical course, a subset of cases present with fast evolution and chemotherapy resistance, leading to high morbidity and mortality. Few clinically validated prognostic markers, such as TP53, are available for use in clinical practice to guide treatment decisions. Recently, several novel prognostically relevant molecular markers have been identified in CLL. We conducted a narrative literature review of the latest findings to evaluate the potential inclusion of these markers in the management of CLL cases.
引用
收藏
页码：271 / 276
页数：6
相关论文
共 61 条
  • [1] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
    Advani, Ranjana H.
    Buggy, Joseph J.
    Sharman, Jeff P.
    Smith, Sonali M.
    Boyd, Thomas E.
    Grant, Barbara
    Kolibaba, Kathryn S.
    Furman, Richard R.
    Rodriguez, Sara
    Chang, Betty Y.
    Sukbuntherng, Juthamas
    Izumi, Raquel
    Hamdy, Ahmed
    Hedrick, Eric
    Fowler, Nathan H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) : 88 - 94
  • [2] [Anonymous], SEER STAT FACT SHEET
  • [3] Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL
    Austen, B
    Powell, JE
    Alvi, A
    Edwards, I
    Hooper, L
    Starczynski, J
    Taylor, AMR
    Fegan, C
    Moss, P
    Stankovic, T
    [J]. BLOOD, 2005, 106 (09) : 3175 - 3182
  • [4] Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion
    Austen, Belinda
    Skowronska, Anna
    Baker, Claire
    Powell, Judith E.
    Gardiner, Anne
    Oscier, David
    Majid, Aneela
    Dyer, Martin
    Siebert, Reiner
    Taylor, A. Malcolm
    Moss, Paul A.
    Stankovic, Tatjana
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (34) : 5448 - 5457
  • [5] NOTCH1 mutations in CLL associated with trisomy 12
    Balatti, Veronica
    Bottoni, Arianna
    Palamarchuk, Alexey
    Alder, Hansjuerg
    Rassenti, Laura Z.
    Kipps, Thomas J.
    Pekarsky, Yuri
    Croce, Carlo M.
    [J]. BLOOD, 2012, 119 (02) : 329 - 331
  • [6] BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO
  • [7] 2-V
  • [8] When mutants gain new powers: news from the mutant p53 field
    Brosh, Ran
    Rotter, Varda
    [J]. NATURE REVIEWS CANCER, 2009, 9 (10) : 701 - 713
  • [9] Bullrich F, 1999, CANCER RES, V59, P24
  • [10] Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations
    Carter, Hannah
    Chen, Sining
    Isik, Leyla
    Tyekucheva, Svitlana
    Velculescu, Victor E.
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Karchin, Rachel
    [J]. CANCER RESEARCH, 2009, 69 (16) : 6660 - 6667
1234567